G-L Qiao1, L Li2, W Cheng3, J Ge1, Z Zhang1, Y Wei1. 1. Department of Pediatric Surgery, Capital Institute of Pediatrics, Beijing, People's Republic of China. 2. Department of Pediatric Surgery, Capital Institute of Pediatrics, Beijing, People's Republic of China. Electronic address: lilongcip@163.com. 3. Department of Surgery, United Family Hospital, Beijing, People's Republic of China; Department of Paediatrics and Department of Surgery, Faculty of Medicine, Nursing and Health Sciences, Monash University, Australia.
Abstract
AIM: The aim of this study is to investigate and identify the predictors associated with the prognosis of patients with hepatoblastoma (HB). METHODS: We retrospectively reviewed 112 children with HB (58 female, 54 male) managed in our institution between May 1st, 2001 and January 30th, 2012. Prognostic factors were evaluated using Kaplan-Meier curves and Cox proportional hazards models. RESULTS: For the entire cohort of 112 patients, the overall median survival was 83.5 months, and the 5-year EFS and OS rates were 57.1% and 63.4%, AFP<100 or >1000 (ng/ml)(HR:2.454, P = 0.013), multifocality (HR:2.852, P = 0.012), vascular invasion (HR:2.272, P = 0.026), metastases (HR:2.654,P = 0.005) and PRETEXT stage (HR:2.817, P = 0.005) were associated with an adverse prognosis in the univariate and multivariable adjusted analysis. Based on these findings, a prognostic scoring system was developed that allotted one point each for these factors. Patients with HB could be stratified into 3 distinct prognostic groups (median and 5-year EFS, respectively): 0 points (105.1 months, 94.1%), 1-2 point (85.8 months, 60.2%), and 3-4 points (31.8 months, 13.5%) (P < 0.001). CONCLUSIONS: We have confirmed the HB prognostic factors associated with survival in the Asian population and established a simple prognostic scoring system.
AIM: The aim of this study is to investigate and identify the predictors associated with the prognosis of patients with hepatoblastoma (HB). METHODS: We retrospectively reviewed 112 children with HB (58 female, 54 male) managed in our institution between May 1st, 2001 and January 30th, 2012. Prognostic factors were evaluated using Kaplan-Meier curves and Cox proportional hazards models. RESULTS: For the entire cohort of 112 patients, the overall median survival was 83.5 months, and the 5-year EFS and OS rates were 57.1% and 63.4%, AFP<100 or >1000 (ng/ml)(HR:2.454, P = 0.013), multifocality (HR:2.852, P = 0.012), vascular invasion (HR:2.272, P = 0.026), metastases (HR:2.654,P = 0.005) and PRETEXT stage (HR:2.817, P = 0.005) were associated with an adverse prognosis in the univariate and multivariable adjusted analysis. Based on these findings, a prognostic scoring system was developed that allotted one point each for these factors. Patients with HB could be stratified into 3 distinct prognostic groups (median and 5-year EFS, respectively): 0 points (105.1 months, 94.1%), 1-2 point (85.8 months, 60.2%), and 3-4 points (31.8 months, 13.5%) (P < 0.001). CONCLUSIONS: We have confirmed the HB prognostic factors associated with survival in the Asian population and established a simple prognostic scoring system.